Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.54

-3.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (7835)	2/10/2003 11:39:22 AM
From: keokalani'nui	Read Replies (1) of 52153

This is the endothelin receptor antagonist that looked pretty good and was certainly part of abbott's thinking when they acquired Knoll. The postponement of bone pain is consistent with P2. Too bad about TTDP; though it looks like they still have hope to hit TTDP in earlier stage prostate cancer. Dow Jones Business News Abbott Labs Stops Atrasentan Study Monday February 10, 9:18 am ET ABBOTT PARK, Ill. (Dow Jones)--Abbott Laboratories said a preliminary analysis of Atrasentan Phase III data from study MOO-211 in end-stage prostrate cancer patients didn't meet its primary endpoint of time-to-disease progression, and therefore will be stopped. However, the study data showed improvements in development of bone pain as an adverse event, prostate-specific antigen levels, and biochemical markets of skeletal progression in patients taking atrasentan versus placebo, the company said in a press release Monday. Additional Phase III studies in prostrate cancer and Phase II studies in other tumor types will continue. The company said these events won't have an impact on its earnings in 2003 or 2004.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next